IFP Advisors Inc Has $1.85 Million Holdings in Intuitive Surgical, Inc. $ISRG

IFP Advisors Inc cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 41.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,339 shares of the medical equipment provider's stock after selling 2,319 shares during the period. IFP Advisors Inc's holdings in Intuitive Surgical were worth $1,852,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Callan Family Office LLC raised its position in shares of Intuitive Surgical by 128.0% in the second quarter. Callan Family Office LLC now owns 32,303 shares of the medical equipment provider's stock valued at $17,554,000 after buying an additional 18,134 shares in the last quarter. TFR Capital LLC. raised its position in shares of Intuitive Surgical by 3.5% in the second quarter. TFR Capital LLC. now owns 7,258 shares of the medical equipment provider's stock valued at $3,944,000 after buying an additional 247 shares in the last quarter. Edge Financial Advisors LLC acquired a new stake in shares of Intuitive Surgical in the second quarter valued at approximately $210,000. Leo Wealth LLC acquired a new stake in shares of Intuitive Surgical in the second quarter valued at approximately $209,000. Finally, US Bancorp DE raised its position in Intuitive Surgical by 40.0% during the second quarter. US Bancorp DE now owns 90,791 shares of the medical equipment provider's stock valued at $49,337,000 after purchasing an additional 25,927 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $429.59 on Friday. The firm's fifty day moving average price is $458.68 and its two-hundred day moving average price is $497.91. The stock has a market cap of $154.00 billion, a PE ratio of 59.91, a PEG ratio of 4.51 and a beta of 1.61. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. During the same quarter in the previous year, the firm posted $1.78 earnings per share. The company's revenue was up 21.4% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Gary S. Guthart sold 29,360 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amy L. Ladd sold 335 shares of the business's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total transaction of $147,631.15. Following the completion of the sale, the director directly owned 739 shares in the company, valued at approximately $325,669.91. This represents a 31.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock valued at $21,716,492 over the last 90 days. 0.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on ISRG shares. Royal Bank Of Canada restated an "outperform" rating and set a $615.00 price objective on shares of Intuitive Surgical in a research report on Tuesday, August 19th. Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group lowered their price objective on shares of Intuitive Surgical from $621.00 to $567.00 and set a "buy" rating for the company in a research report on Wednesday, October 1st. UBS Group boosted their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Evercore ISI lowered their price objective on shares of Intuitive Surgical from $535.00 to $450.00 and set an "in-line" rating for the company in a research report on Tuesday, October 7th. Fourteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Intuitive Surgical has an average rating of "Moderate Buy" and an average price target of $589.43.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.